Recent studies have centered on the overlap of GLP-1|glucose-dependent insulinotropic polypeptide|GCGR agonist therapies and DA neurotransmission. While GIP activators are widely employed for treating type 2 diabetes, their potential effects on motivation circuits, specifically mediated by dopami